Australia · Delayed Price · Currency is AUD Noxopharm Company Description
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia.
It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions.
The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types.
Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.
Contact Details
Address: 60 Linksley Avenue Glenhaven, 2156 Australia | |
| Phone | 61 2 9144 2223 |
| Website | noxopharm.com |
Stock Details
| Ticker Symbol | NOX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000NOX9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gisela Mautner | Chief Executive Officer, Executive MD and Director |
| Shawn Van Boheemen FCPA, J.P. | Chief Financial Officer |
| Jeanette Bell Ph.D. | Chief Operating Officer |
| Dr. John Wilkinson B.Sc., Ph.D. | Chief Scientific Officer of Oncology |
| Dr. Olivier Laczka B.S., M.Sc., Ph.D. | Chief Scientific Officer of Inflammation |
| David James Franks BEc, C.A., F Fin, J.P. | Company Secretary |